Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells

Carcinogenesis

Volumn 35, Issue 1, 2014, Pages 192-200

  Odaka, Yoshinobu ^a   Xu, Baoshan ^a   Luo, Yan ^a   Shen, Tao ^a   Shang, Chaowei ^a   Wu, Yang ^a   Zhou, Hongyu ^a   Huang, Shile ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; ARTEMISININ; ARTESUNATE; DIHYDROARTEMISININ; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TUMOR CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; ARTEMISININS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, P53; HUMANS; MULTIPROTEIN COMPLEXES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84891368738     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt277     Document Type: Article

References (68)

1. Malempati,S. et al. (2012) Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr. Blood Cancer, 59, 5-10.
2. Ognjanovic,S. et al. (2009) Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer, 115, 4218-4226.
3. Punyko,J.A. et al. (2005) Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer, 103, 1475-1483.
4. Sorensen,P.H. et al. (2002) PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol., 20, 2672-2679.
5. Barr,F.G. (2001) Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene, 20, 5736-5746.
6. Li,Y. (2012) Qinghaosu (artemisinin): chemistry and pharmacology. Acta Pharmacol. Sin., 33, 1141-1146.
7. Fairhurst,R.M. et al. (2012) Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am. J. Trop. Med. Hyg., 87, 231-241.
8. Li,Q.G. et al. (1998) The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. J. Pharm. Pharmacol., 50, 173-182.
9. Sun,W.C. et al. (1992) [Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro]. Zhongguo Yao Li Xue Bao, 13, 541-543.
10. Moore,J.C. et al. (1995) Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett., 98, 83-87.
11. Berger,T.G. et al. (2005) Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol. Rep., 14, 1599-1603.
12. Zhang,Z.Y. et al. (2008) [Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial]. Zhong Xi Yi Jie He Xue Bao, 6, 134-138.
13. Huang,X.J. et al. (2007) Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. J. Pharm. Pharmacol., 59, 849-856.
14. Lu,J.J. et al. (2010) Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem. Pharmacol., 80, 22-30.
15. Gao,N. et al. (2011) Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo. Apoptosis, 16, 511-523.
16. Wang,S.J. et al. (2010) Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett., 293, 99-108.
17. Wang,S.J. et al. (2011) Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway. Cancer Chemother. Pharmacol., 68, 1421-1430.
18. Zhou,H.J. et al. (2010) Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro. Cancer Chemother. Pharmacol., 66, 21-29.
19. Zhang,C.Z. et al. (2012) Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem. Pharmacol., 83, 1278-1289.
20. Wu,B. et al. (2012) Dihydroartiminisin inhibits the growth and metastasis of epithelial ovarian cancer. Oncol. Rep., 27, 101-108.
21. Laplante,M. et al. (2012) mTOR signaling in growth control and disease. Cell, 149, 274-293.
22. Dancey,J. (2010) mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol., 7, 209-219.
23. Hara,K. et al. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell, 110, 177-189.
24. Kim,D.H. et al. (2002) mTOR interacts with raptor to form a nutrientsensitive complex that signals to the cell growth machinery. Cell, 110, 163-175.
25. Kim,D.H. et al. (2003) GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell, 11, 895-904.
26. Loewith,R. et al. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell, 10, 457-468.
27. Sancak,Y. et al. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell, 25, 903-915.
28. Vander Haar,E. et al. (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol., 9, 316-323.
29. Peterson,T.R. et al. (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell, 137, 873-886.
30. Sarbassov,D.D. et al. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol., 14, 1296-1302.
31. Jacinto,E. et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol., 6, 1122-1128.
32. Sarbassov,D.D. et al. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-1101.
33. Frias,M.A. et al. (2006) mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol., 16, 1865-1870.
34. Jacinto,E. et al. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell, 127, 125-137.
35. Yang,Q. et al. (2006) Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev., 20, 2820-2832.
36. Pearce,L.R. et al. (2007) Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J., 405, 513-522.
37. Woo,S.Y. et al. (2007) PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J. Biol. Chem., 282, 25604-25612.
38. García-Martínez,J.M. et al. (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid- induced protein kinase 1 (SGK1). Biochem. J., 416, 375-385.
39. Liu,L. et al. (2008) Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene, 27, 4998-5010.
40. Liu,L. et al. (2010) Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J. Biol. Chem., 285, 38362-38373.
41. Sarbassov,D.D. et al. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell, 22, 159-168.
42. Haruta,T. et al. (2000) A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol. Endocrinol., 14, 783-794.
43. Shah,O.J. et al. (2004) Inappropriate activation of the TSC/Rheb/mTOR/ S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol., 14, 1650-1656.
44. O'Reilly,K.E. et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 66, 1500-1508.
45. Hashemolhosseini,S. et al. (1998) Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem., 273, 14424-14429.
46. Gera,J.F. et al. (2004) AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J. Biol. Chem., 279, 2737-2746.
47. Albers,M.W. et al. (1993) FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. J. Biol. Chem., 268, 22825-22829.
48. Morice,W.G. et al. (1993) Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J. Biol. Chem., 268, 22737-22745.
49. Beuvink,I. et al. (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell, 120, 747-759.
50. Nourse,J. et al. (1994) Interleukin-2-mediated elimination of the p27Kip1 cyclin- dependent kinase inhibitor prevented by rapamycin. Nature, 372, 570-573.
51. Marx,S.O. et al. (1995) Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res., 76, 412-417.
52. Yu,K. et al. (2001) mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer, 8, 249-258.
53. Hudson,C.C. et al. (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol., 22, 7004-7014.
54. Guba,M. et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med., 8, 128-135.
55. Liu,L. et al. (2010) Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway. PLoS One, 5, e10578.
56. Mabuchi,S. et al. (2007) RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res., 67, 2408-2413.
57. Jundt,F. et al. (2005) A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood, 106, 1801-1807.
58. Felix,C.A. et al. (1992) Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res., 52, 2243-2247.
59. Huang,S. et al. (2001) p53/p21(CIP1) cooperate in enforcing rapamycininduced G(1) arrest and determine the cellular response to rapamycin. Cancer Res., 61, 3373-3381.
60. Zhou,H. et al. (2010) The antitumor activity of the fungicide ciclopirox. Int. J. Cancer, 127, 2467-2477.
61. Han,X. et al. (2012) Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cells. Carcinogenesis, 33, 868-875.
62. Liu,L. et al. (2006) Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene, 25, 7029-7040.
63. Malumbres,M. et al. (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 9, 153-166.
64. Riley,T. et al. (2008) Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol., 9, 402-412.
65. Zhao,Y.G. et al. (2012) Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway. J. Immunol., 189, 4417-4425.
66. Thoreen,C.C. et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem., 284, 8023-8032.
67. Yellen,P. et al. (2011) High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle, 10, 3948-3956.
68. Dowling,R.J. et al. (2010) mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science, 328, 1172-1176.